Alnylam Pharmaceuticals
ALNY
198 hedge funds and large institutions have $3.74B invested in Alnylam Pharmaceuticals in 2014 Q1 according to their latest regulatory filings, with 45 funds opening new positions, 70 increasing their positions, 64 reducing their positions, and 15 closing their positions.
200% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 15
17% more funds holding
Funds holding: 169 → 198 (+29)
9% more repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 64
5% more capital invested
Capital invested by funds: $3.57B → $3.74B (+$167M)
53% less call options, than puts
Call options by funds: $27.9M | Put options by funds: $59.7M
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
+$35.2M |
| 2 |
GTP
Global Thematic Partners
New York
|
+$33M |
| 3 |
CCI
Columbus Circle Investors
|
+$26.8M |
| 4 |
DM
Deerfield Management
New York
|
+$23.4M |
| 5 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$13.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CWAM
Columbia Wanger Asset Management
Chicago,
Illinois
|
-$78M |
| 2 |
AWG
Alpha Wave Global
New York
|
-$64.3M |
| 3 |
SPC
Slate Path Capital
New York
|
-$45.6M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$22.1M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$17M |
ALNY Hedge Fund Activity: Q1 2014 in Review
198 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in Alnylam Pharmaceuticals (ALNY) for Q1 2014, worth a combined $3.74B — up 4.7% from $3.57B a quarter earlier.
Buyers outnumbered sellers: 45 funds opened new ALNY positions and 15 closed out — a net gain of 30 holders — while 70 added to existing stakes and 64 trimmed.
The largest buyer was Franklin Resources, adding an estimated $35.2M. The largest seller was Columbia Wanger Asset Management, cutting an estimated $78M.
- 198 institutional investors held Alnylam Pharmaceuticals (ALNY) as of Q1 2014, up from 169 in Q4 2013.
- Funds reported $3.74B of Alnylam Pharmaceuticals stock for Q1 2014, up 4.7% quarter-over-quarter.
- 45 funds opened new Alnylam Pharmaceuticals positions in Q1 2014 and 15 closed out, a net change of +30 holders.
- The largest Alnylam Pharmaceuticals buyer in Q1 2014 was Franklin Resources, an estimated $35.2M added.
- The largest Alnylam Pharmaceuticals seller in Q1 2014 was Columbia Wanger Asset Management, an estimated $78M sold.
Based on aggregated 13F filings for Q1 2014.